Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Multifunctional Alleles: A novel method for the generation of "All-In-One" null and conditional alleles.

Pefanis E, Schoenherr C, Persaud T, Zhang Y, Golubov J, Wang B, Skokos D, Zambrowicz B, Murphy AJ, Economides AN.

Methods. 2019 Jul 15;164-165:91-99. doi: 10.1016/j.ymeth.2019.04.013. Epub 2019 Apr 27.

2.

NOTUM inhibition increases endocortical bone formation and bone strength.

Brommage R, Liu J, Vogel P, Mseeh F, Thompson AY, Potter DG, Shadoan MK, Hansen GM, Jeter-Jones S, Cui J, Bright D, Bardenhagen JP, Doree DD, Movérare-Skrtic S, Nilsson KH, Henning P, Lerner UH, Ohlsson C, Sands AT, Tarver JE, Powell DR, Zambrowicz B, Liu Q.

Bone Res. 2019 Jan 8;7:2. doi: 10.1038/s41413-018-0038-3. eCollection 2019.

3.

Mice harboring the human SLC30A8 R138X loss-of-function mutation have increased insulin secretory capacity.

Kleiner S, Gomez D, Megra B, Na E, Bhavsar R, Cavino K, Xin Y, Rojas J, Dominguez-Gutierrez G, Zambrowicz B, Carrat G, Chabosseau P, Hu M, Murphy AJ, Yancopoulos GD, Rutter GA, Gromada J.

Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7642-E7649. doi: 10.1073/pnas.1721418115. Epub 2018 Jul 23.

4.

A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.

Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, Liu Y, Kozlitina J, Stender S, Wood GC, Stepanchick AN, Still MD, McCarthy S, O'Dushlaine C, Packer JS, Balasubramanian S, Gosalia N, Esopi D, Kim SY, Mukherjee S, Lopez AE, Fuller ED, Penn J, Chu X, Luo JZ, Mirshahi UL, Carey DJ, Still CD, Feldman MD, Small A, Damrauer SM, Rader DJ, Zambrowicz B, Olson W, Murphy AJ, Borecki IB, Shuldiner AR, Reid JG, Overton JD, Yancopoulos GD, Hobbs HH, Cohen JC, Gottesman O, Teslovich TM, Baras A, Mirshahi T, Gromada J, Dewey FE.

N Engl J Med. 2018 Mar 22;378(12):1096-1106. doi: 10.1056/NEJMoa1712191.

5.

Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice.

Kim J, Okamoto H, Huang Z, Anguiano G, Chen S, Liu Q, Cavino K, Xin Y, Na E, Hamid R, Lee J, Zambrowicz B, Unger R, Murphy AJ, Xu Y, Yancopoulos GD, Li WH, Gromada J.

Cell Metab. 2017 Jun 6;25(6):1348-1361.e8. doi: 10.1016/j.cmet.2017.05.006.

6.

LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice.

Powell DR, Smith MG, Doree DD, Harris AL, Greer J, DaCosta CM, Thompson A, Jeter-Jones S, Xiong W, Carson KG, Goodwin NC, Harrison BA, Rawlins DB, Strobel ED, Gopinathan S, Wilson A, Mseeh F, Zambrowicz B, Ding ZM.

J Pharmacol Exp Ther. 2017 Jul;362(1):85-97. doi: 10.1124/jpet.117.240820. Epub 2017 Apr 25.

PMID:
28442582
7.

ANGPTL8 Blockade With a Monoclonal Antibody Promotes Triglyceride Clearance, Energy Expenditure, and Weight Loss in Mice.

Gusarova V, Banfi S, Alexa-Braun CA, Shihanian LM, Mintah IJ, Lee JS, Xin Y, Su Q, Kamat V, Cohen JC, Hobbs HH, Zambrowicz B, Yancopoulos GD, Murphy AJ, Gromada J.

Endocrinology. 2017 May 1;158(5):1252-1259. doi: 10.1210/en.2016-1894.

8.

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.

Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M.

J Clin Oncol. 2017 Jan;35(1):14-23. Epub 2016 Oct 28.

PMID:
27918724
9.

Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain.

Kostich W, Hamman BD, Li YW, Naidu S, Dandapani K, Feng J, Easton A, Bourin C, Baker K, Allen J, Savelieva K, Louis JV, Dokania M, Elavazhagan S, Vattikundala P, Sharma V, Das ML, Shankar G, Kumar A, Holenarsipur VK, Gulianello M, Molski T, Brown JM, Lewis M, Huang Y, Lu Y, Pieschl R, O'Malley K, Lippy J, Nouraldeen A, Lanthorn TH, Ye G, Wilson A, Balakrishnan A, Denton R, Grace JE, Lentz KA, Santone KS, Bi Y, Main A, Swaffield J, Carson K, Mandlekar S, Vikramadithyan RK, Nara SJ, Dzierba C, Bronson J, Macor JE, Zaczek R, Westphal R, Kiss L, Bristow L, Conway CM, Zambrowicz B, Albright CF.

J Pharmacol Exp Ther. 2016 Sep;358(3):371-86. doi: 10.1124/jpet.116.235333. Epub 2016 Jul 13.

10.

Fatty acid desaturase 1 knockout mice are lean with improved glycemic control and decreased development of atheromatous plaque.

Powell DR, Gay JP, Smith M, Wilganowski N, Harris A, Holland A, Reyes M, Kirkham L, Kirkpatrick LL, Zambrowicz B, Hansen G, Platt KA, van Sligtenhorst I, Ding ZM, Desai U.

Diabetes Metab Syndr Obes. 2016 Jun 22;9:185-99. doi: 10.2147/DMSO.S106653. eCollection 2016.

11.

C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice.

Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee HC, Siao CJ, Brydges S, LaRosa E, Bai Y, Fury W, Burfeind P, Zamfirova R, Warshaw G, Orengo J, Oyejide A, Fralish M, Auerbach W, Poueymirou W, Freudenberg J, Gong G, Zambrowicz B, Valenzuela D, Yancopoulos G, Murphy A, Thurston G, Lai KM.

Sci Rep. 2016 Mar 16;6:23204. doi: 10.1038/srep23204.

12.

Dentin Dysplasia in Notum Knockout Mice.

Vogel P, Read RW, Hansen GM, Powell DR, Kantaputra PN, Zambrowicz B, Brommage R.

Vet Pathol. 2016 Jul;53(4):853-62. doi: 10.1177/0300985815626778. Epub 2016 Feb 29.

PMID:
26926082
13.

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.

Mudaliar S, Polidori D, Zambrowicz B, Henry RR.

Diabetes Care. 2015 Dec;38(12):2344-53. doi: 10.2337/dc15-0642. Review.

PMID:
26604280
14.

Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation.

Kim JJ, Wang H, Terc JD, Zambrowicz B, Yang QM, Khan WI.

Am J Physiol Gastrointest Liver Physiol. 2015 Sep 15;309(6):G455-65. doi: 10.1152/ajpgi.00299.2014. Epub 2015 Jul 23.

15.

Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.

Powell DR, Gay JP, Wilganowski N, Doree D, Savelieva KV, Lanthorn TH, Read R, Vogel P, Hansen GM, Brommage R, Ding ZM, Desai U, Zambrowicz B.

Front Endocrinol (Lausanne). 2015 Jun 2;6:86. doi: 10.3389/fendo.2015.00086. eCollection 2015.

16.

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.

Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P.

Diabetes Care. 2015 Jul;38(7):1181-8. doi: 10.2337/dc14-2806. Epub 2015 Jun 6.

17.

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.

Powell DR, Smith MG, Doree DD, Harris AL, Xiong WW, Mseeh F, Wilson A, Gopinathan S, Diaz D, Goodwin NC, Harrison B, Strobel E, Rawlins DB, Carson K, Zambrowicz B, Ding ZM.

Pharmacol Res Perspect. 2015 Mar;3(2):e00129. doi: 10.1002/prp2.129. Epub 2015 Mar 31.

18.

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.

Powell DR, Doree D, Jeter-Jones S, Ding ZM, Zambrowicz B, Sands A.

Diabetes Metab Syndr Obes. 2015 Feb 26;8:121-7. doi: 10.2147/DMSO.S76342. eCollection 2015.

19.

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.

Lapuerta P, Zambrowicz B, Strumph P, Sands A.

Diab Vasc Dis Res. 2015 Mar;12(2):101-10. doi: 10.1177/1479164114563304. Review.

PMID:
25690134
20.

Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.

Pavel M, Hörsch D, Caplin M, Ramage J, Seufferlein T, Valle J, Banks P, Lapuerta P, Sands A, Zambrowicz B, Fleming D, Wiedenmann B.

J Clin Endocrinol Metab. 2015 Apr;100(4):1511-9. doi: 10.1210/jc.2014-2247. Epub 2015 Jan 30.

PMID:
25636046
21.

LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion.

Zambrowicz B, Lapuerta P, Strumph P, Banks P, Wilson A, Ogbaa I, Sands A, Powell D.

Clin Ther. 2015 Jan 1;37(1):71-82.e12. doi: 10.1016/j.clinthera.2014.10.026. Epub 2014 Dec 17.

PMID:
25529979
22.

Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.

Rosenstock J, Cefalu WT, Lapuerta P, Zambrowicz B, Ogbaa I, Banks P, Sands A.

Diabetes Care. 2015 Mar;38(3):431-8. doi: 10.2337/dc14-0890. Epub 2014 Sep 11.

23.

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.

Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A.

Endocr Relat Cancer. 2014 Oct;21(5):705-14. doi: 10.1530/ERC-14-0173. Epub 2014 Jul 10.

24.

Genetic deletion of Mst1 alters T cell function and protects against autoimmunity.

Salojin KV, Hamman BD, Chang WC, Jhaver KG, Al-Shami A, Crisostomo J, Wilkins C, Digeorge-Foushee AM, Allen J, Patel N, Gopinathan S, Zhou J, Nouraldeen A, Jessop TC, Bagdanoff JT, Augeri DJ, Read R, Vogel P, Swaffield J, Wilson A, Platt KA, Carson KG, Main A, Zambrowicz BP, Oravecz T.

PLoS One. 2014 May 22;9(5):e98151. doi: 10.1371/journal.pone.0098151. eCollection 2014.

25.

Effect of LX4211 on glucose homeostasis and body composition in preclinical models.

Powell DR, DaCosta CM, Smith M, Doree D, Harris A, Buhring L, Heydorn W, Nouraldeen A, Xiong W, Yalamanchili P, Mseeh F, Wilson A, Shadoan M, Zambrowicz B, Ding ZM.

J Pharmacol Exp Ther. 2014 Aug;350(2):232-42. doi: 10.1124/jpet.114.214304. Epub 2014 May 21.

PMID:
24849925
26.

High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes.

Brommage R, Liu J, Hansen GM, Kirkpatrick LL, Potter DG, Sands AT, Zambrowicz B, Powell DR, Vogel P.

Bone Res. 2014 Oct 28;2:14034. doi: 10.1038/boneres.2014.34. eCollection 2014.

27.

Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.

Zambrowicz B, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Boehm KA, Ruff D, Powell D, Sands A.

Clin Ther. 2013 Aug;35(8):1162-1173.e8. doi: 10.1016/j.clinthera.2013.06.011. Epub 2013 Jul 31.

PMID:
23911260
28.

Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine.

Margolis KG, Stevanovic K, Li Z, Yang QM, Oravecz T, Zambrowicz B, Jhaver KG, Diacou A, Gershon MD.

Gut. 2014 Jun;63(6):928-37. doi: 10.1136/gutjnl-2013-304901. Epub 2013 Jun 7.

29.

Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.

Lapuerta P, Rosenstock J, Zambrowicz B, Powell DR, Ogbaa I, Freiman J, Cefalu WT, Banks P, Frazier K, Kelly M, Sands A.

Clin Cardiol. 2013 Jul;36(7):367-71. doi: 10.1002/clc.22125. Epub 2013 Apr 29.

30.

LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.

Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, Mseeh F, Shadoan MK, Sands A, Zambrowicz B, Ding ZM.

J Pharmacol Exp Ther. 2013 May;345(2):250-9. doi: 10.1124/jpet.113.203364. Epub 2013 Mar 13.

PMID:
23487174
31.

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.

Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Smith M, Ruff D, Sands A, Powell D.

Clin Ther. 2013 Mar;35(3):273-285.e7. doi: 10.1016/j.clinthera.2013.01.010. Epub 2013 Feb 21.

PMID:
23433601
32.

Improved glycemic control in mice lacking Sglt1 and Sglt2.

Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, Rodriguez LA, Harris A, Buhring L, Platt KA, Vogel P, Brommage R, Shadoan MK, Sands AT, Zambrowicz B.

Am J Physiol Endocrinol Metab. 2013 Jan 15;304(2):E117-30. doi: 10.1152/ajpendo.00439.2012. Epub 2012 Nov 13.

33.

Keratinocyte migration in the developing eyelid requires LIMK2.

Rice DS, Hansen GM, Liu F, Crist MJ, Newhouse MM, Potter D, Xu N, Abuin A, Vogel PJ, Zambrowicz BP.

PLoS One. 2012;7(10):e47168. doi: 10.1371/journal.pone.0047168. Epub 2012 Oct 5.

34.

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, Rawlins DB, Goodwin NC, Mabon R, Harrison BA, Wilson A, Sands A, Powell DR.

Clin Pharmacol Ther. 2012 Aug;92(2):158-69. doi: 10.1038/clpt.2012.58. Epub 2012 Jul 4.

35.

Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex.

Yoshino H, Miyamae T, Hansen G, Zambrowicz B, Flynn M, Pedicord D, Blat Y, Westphal RS, Zaczek R, Lewis DA, Gonzalez-Burgos G.

J Physiol. 2011 Oct 15;589(Pt 20):4857-84. doi: 10.1113/jphysiol.2011.212225. Epub 2011 Aug 1.

36.

Congenital hydrocephalus in genetically engineered mice.

Vogel P, Read RW, Hansen GM, Payne BJ, Small D, Sands AT, Zambrowicz BP.

Vet Pathol. 2012 Jan;49(1):166-81. doi: 10.1177/0300985811415708. Epub 2011 Jul 11.

PMID:
21746835
37.

The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.

Brown PM, Drossman DA, Wood AJ, Cline GA, Frazier KS, Jackson JI, Bronner J, Freiman J, Zambrowicz B, Sands A, Gershon MD.

Gastroenterology. 2011 Aug;141(2):507-16. doi: 10.1053/j.gastro.2011.05.005. Epub 2011 May 18.

38.

Lrp5 functions in bone to regulate bone mass.

Cui Y, Niziolek PJ, MacDonald BT, Zylstra CR, Alenina N, Robinson DR, Zhong Z, Matthes S, Jacobsen CM, Conlon RA, Brommage R, Liu Q, Mseeh F, Powell DR, Yang QM, Zambrowicz B, Gerrits H, Gossen JA, He X, Bader M, Williams BO, Warman ML, Robling AG.

Nat Med. 2011 Jun;17(6):684-91. doi: 10.1038/nm.2388. Epub 2011 May 22.

39.

Profound obesity secondary to hyperphagia in mice lacking kinase suppressor of ras 2.

Revelli JP, Smith D, Allen J, Jeter-Jones S, Shadoan MK, Desai U, Schneider M, van Sligtenhorst I, Kirkpatrick L, Platt KA, Suwanichkul A, Savelieva K, Gerhardt B, Mitchell J, Syrewicz J, Zambrowicz B, Hamman BD, Vogel P, Powell DR.

Obesity (Silver Spring). 2011 May;19(5):1010-8. doi: 10.1038/oby.2010.282. Epub 2010 Dec 2.

40.

A mouse knockout library for secreted and transmembrane proteins.

Tang T, Li L, Tang J, Li Y, Lin WY, Martin F, Grant D, Solloway M, Parker L, Ye W, Forrest W, Ghilardi N, Oravecz T, Platt KA, Rice DS, Hansen GM, Abuin A, Eberhart DE, Godowski P, Holt KH, Peterson A, Zambrowicz BP, de Sauvage FJ.

Nat Biotechnol. 2010 Jul;28(7):749-55. doi: 10.1038/nbt.1644. Epub 2010 Jun 20.

PMID:
20562862
41.

Situs inversus in Dpcd/Poll-/-, Nme7-/- , and Pkd1l1-/- mice.

Vogel P, Read R, Hansen GM, Freay LC, Zambrowicz BP, Sands AT.

Vet Pathol. 2010 Jan;47(1):120-31. doi: 10.1177/0300985809353553.

PMID:
20080492
42.

GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4.

Sonnenburg WK, Yu D, Lee EC, Xiong W, Gololobov G, Key B, Gay J, Wilganowski N, Hu Y, Zhao S, Schneider M, Ding ZM, Zambrowicz BP, Landes G, Powell DR, Desai U.

J Lipid Res. 2009 Dec;50(12):2421-9. doi: 10.1194/jlr.M900145-JLR200. Epub 2009 Jun 21.

43.

Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL).

Lee EC, Desai U, Gololobov G, Hong S, Feng X, Yu XC, Gay J, Wilganowski N, Gao C, Du LL, Chen J, Hu Y, Zhao S, Kirkpatrick L, Schneider M, Zambrowicz BP, Landes G, Powell DR, Sonnenburg WK.

J Biol Chem. 2009 May 15;284(20):13735-45. doi: 10.1074/jbc.M807899200. Epub 2009 Mar 23.

44.

Large-scale gene trapping in C57BL/6N mouse embryonic stem cells.

Hansen GM, Markesich DC, Burnett MB, Zhu Q, Dionne KM, Richter LJ, Finnell RH, Sands AT, Zambrowicz BP, Abuin A.

Genome Res. 2008 Oct;18(10):1670-9. doi: 10.1101/gr.078352.108. Epub 2008 Sep 17.

45.

High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes.

Brommage R, Desai U, Revelli JP, Donoviel DB, Fontenot GK, Dacosta CM, Smith DD, Kirkpatrick LL, Coker KJ, Donoviel MS, Eberhart DE, Holt KH, Kelly MR, Paradee WJ, Philips AV, Platt KA, Suwanichkul A, Hansen GM, Sands AT, Zambrowicz BP, Powell DR.

Obesity (Silver Spring). 2008 Oct;16(10):2362-7. doi: 10.1038/oby.2008.361. Epub 2008 Jul 31.

46.

Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract.

Liu Q, Yang Q, Sun W, Vogel P, Heydorn W, Yu XQ, Hu Z, Yu W, Jonas B, Pineda R, Calderon-Gay V, Germann M, O'Neill E, Brommage R, Cullinan E, Platt K, Wilson A, Powell D, Sands A, Zambrowicz B, Shi ZC.

J Pharmacol Exp Ther. 2008 Apr;325(1):47-55. doi: 10.1124/jpet.107.132670. Epub 2008 Jan 11.

PMID:
18192499
47.

Mouse Fkbp8 activity is required to inhibit cell death and establish dorso-ventral patterning in the posterior neural tube.

Wong RL, Wlodarczyk BJ, Min KS, Scott ML, Kartiko S, Yu W, Merriweather MY, Vogel P, Zambrowicz BP, Finnell RH.

Hum Mol Genet. 2008 Feb 15;17(4):587-601. Epub 2007 Nov 13.

PMID:
18003640
48.

Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice.

Desai U, Lee EC, Chung K, Gao C, Gay J, Key B, Hansen G, Machajewski D, Platt KA, Sands AT, Schneider M, Van Sligtenhorst I, Suwanichkul A, Vogel P, Wilganowski N, Wingert J, Zambrowicz BP, Landes G, Powell DR.

Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11766-71. Epub 2007 Jul 3.

49.

Gene trap mutagenesis.

Abuin A, Hansen GM, Zambrowicz B.

Handb Exp Pharmacol. 2007;(178):129-47. Review.

PMID:
17203654
50.

The knockout mouse project.

Austin CP, Battey JF, Bradley A, Bucan M, Capecchi M, Collins FS, Dove WF, Duyk G, Dymecki S, Eppig JT, Grieder FB, Heintz N, Hicks G, Insel TR, Joyner A, Koller BH, Lloyd KC, Magnuson T, Moore MW, Nagy A, Pollock JD, Roses AD, Sands AT, Seed B, Skarnes WC, Snoddy J, Soriano P, Stewart DJ, Stewart F, Stillman B, Varmus H, Varticovski L, Verma IM, Vogt TF, von Melchner H, Witkowski J, Woychik RP, Wurst W, Yancopoulos GD, Young SG, Zambrowicz B.

Nat Genet. 2004 Sep;36(9):921-4.

Supplemental Content

Loading ...
Support Center